Frankfurt
21.01.26 | 15:25
0,125 Euro
-19,87 % -0,031
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,132 | 0,141 | 21.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Creo Medical - FY25 results validate growth strategy | 148 | Edison Investment Research | Creo Medical has reported its headline FY25 results, delivering fully on its guided revenue and cost savings targets for the year. Core revenues were reported at £6.0m, 50% y-o-y growth and within the... ► Artikel lesen | |
| CREO MEDICAL Aktie jetzt für 0€ handeln | |||||
| Di | TRADING UPDATES: Staffline and Creo Medical report higher earnings | 1 | Alliance News | ||
| Di | Creo Medical Group - FY25 Trading Update | - | RNS | ||
| 14.01. | Creo Medical Group - Award of Shares under Share Incentive Plan | - | RNS | ||
| 27.10.25 | Creo Medical Group - Notice of Capital Markets Day | - | RNS | ||
| 07.10.25 | Creo Medical Group - Capital Markets Day update | - | RNS | ||
| 22.09.25 | Creo Medical Group - Unaudited results for the six months ended 30 June | - | RNS | ||
| 11.09.25 | Creo Medical Group - Notice of Results | - | RNS | ||
| 12.08.25 | Creo Medical Group - Director/PDMR Share Dealing | - | RNS | ||
| 04.08.25 | Creo Medical's Speedboat device helped patient avoid major surgery | 1 | Investing.com | ||
| 04.08.25 | Creo Medical: Speedboat-Technologie erspart Patientin schwere Operation | 1 | Investing.com Deutsch | ||
| 04.08.25 | Creo Medical Group - Speedboat patient testimonial | - | RNS | ||
| 22.07.25 | Creo Medical - H1 momentum underpins FY25 confidence | 403 | Edison Investment Research | Creo Medical's H125 trading update delivered early results from the company's streamlined focus on its core technology franchise and cost optimisation, following a strategic review in H224. Core technology... ► Artikel lesen | |
| 11.06.25 | Creo Medical - SpydrBlade Flex set to enter the US market | 430 | Edison Investment Research | Creo Medical has received 510(k) FDA clearance for its latest endoscopic electrosurgical device, SpydrBlade Flex, strengthening its strategic foothold in the high-value US market. SpydrBlade Flex is... ► Artikel lesen | |
| 27.05.25 | Creo Medical - Rightsized and refocused | 346 | Edison Investment Research | Creo Medical's FY24 results unveiled a streamlined business model focused on its core advanced energy platform, following the divestment of a 51% stake in its consumables arm, Creo Medical Europe (CME... ► Artikel lesen | |
| 03.03.25 | Creo Medical - Refreshed business outlook | 309 | Edison Investment Research | Creo Medical has released its FY24 trading update, summarising an eventful year for the company and its strategic priorities. The period saw Creo reaffirm its focus on its core technology platform and... ► Artikel lesen | |
| 13.02.25 | Creo Medical - Consumables business divestment concludes | 334 | Edison Investment Research | Creo Medical has completed the sale of the majority (51%) stake in its European consumable business to Chinese medical device manufacturer Micro-Tech for net proceeds of c €30m (c £25m). The deal valued... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HVIVO | 0,054 | -2,70 % | hVIVO PLC - Appointment of Non-Executive Director | ||
| PAVMED | 11,970 | 0,00 % | Should you chase the rally in PAVmed stock after it quadrupled on Wednesday? | ||
| SIEMENS HEALTHINEERS | 43,630 | -2,00 % | JPMORGAN stuft Siemens Healthineers auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Siemens Healthineers mit einem Kursziel von 61,30 Euro auf "Overweight" belassen. Der Konzernchef sowie der Finanzvorstand hätten... ► Artikel lesen | |
| FRESENIUS | 47,640 | +1,10 % | Fresenius: Nach 5-Jahres-Hoch - Analysten weiter optimistisch | Der Trading-Tipp des Tages ist diesmal Fresenius. In diesem Jahr läuft es für die Aktie bisher sehr gut. Gestern erreichte das Papier sogar ein 5-Jahres-Hoch. Heute findet sich Fresenius zwar am DAX-Ende... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 36,630 | +1,81 % | DAX-Check LIVE: Aixtron, BASF, Bayer, Fresenius Medical Care, K+S, SAP, Schaeffler im Fokus | Nach sieben Rekordtagen in Folge haben am Mittwoch am deutschen Aktienmarkt die Verkäufer die Oberhand gewonnen. Der DAX schloss 0,5 Prozent tiefer bei 25.286 Punkten. Nach sieben Rekordtagen in Folge... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 35,200 | -0,73 % | BERNSTEIN RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Carl Zeiss Meditec vor Zahlen mit einem Kursziel von 50,55 Euro auf "Outperform" belassen. Das erste Quartal... ► Artikel lesen | |
| HEARTFLOW | 33,550 | -1,87 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| ANTERIS TECHNOLOGIES GLOBAL | 6,060 | 0,00 % | Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic | MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR), a global structural heart company committed... ► Artikel lesen | |
| GENEDX | 100,04 | +0,36 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PROGYNY | 25,450 | +0,28 % | Forecasting The Future: 6 Analyst Projections For Progyny | ||
| PRIVIA HEALTH GROUP | 23,600 | +1,68 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| RXSIGHT | 9,950 | 0,00 % | Expert Outlook: RxSight Through The Eyes Of 5 Analysts | ||
| BRIGHTSPRING HEALTH SERVICES | 39,210 | +1,24 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 23,300 | 0,00 % | Alignment Healthcare Named to the 2026 Fortune World's Most Admired Companies List for First Time | ||
| PROCEPT BIOROBOTICS | 30,940 | +2,08 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen |
Das Unternehmen CREO MEDICAL GROUP PLC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -19,87 % bei einem Aktienkurs von 0,125 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CREO MEDICAL GROUP PLC finden Sie auf Wallstreet Online.